Controversies in adverse drug reaction reporting.
作者信息
Juergens J P
出版信息
Am J Hosp Pharm. 1990 Jan;47(1):76-7.
PMID:2301428
Abstract
摘要
相似文献
1
Controversies in adverse drug reaction reporting.
Am J Hosp Pharm. 1990 Jan;47(1):76-7.
2
Toward improved adverse event/suspected adverse drug reaction reporting.迈向改进不良事件/疑似药物不良反应报告。
Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):89-91. doi: 10.1002/pds.800.
3
Strategy for surveillance of adverse drug events.药品不良事件监测策略。
Food Drug Law J. 2007;62(3):605-16.
4
National adverse drug reaction reporting. 1984-1989.国家药品不良反应报告。1984 - 1989年。
Arch Intern Med. 1991 Aug;151(8):1645-7.
5
FDA attempting to overcome major roadblocks in monitoring drug safety.美国食品药品监督管理局正在试图克服药品安全监测中的重大障碍。
J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. doi: 10.1093/jnci/97.12.872.
6
Safety in numbers--monitoring risk in approved drugs.人多势众——监测已获批药物的风险
N Engl J Med. 2005 Mar 24;352(12):1173-6. doi: 10.1056/NEJMp058029.
7
The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.美国食品药品监督管理局的哨兵计划：拓展医疗产品安全的视野。
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:9-11. doi: 10.1002/pds.2311.
8
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.1969 - 2002年美国药品不良事件监测与药物撤市：报告疑似不良反应的重要性
Arch Intern Med. 2005 Jun 27;165(12):1363-9. doi: 10.1001/archinte.165.12.1363.
9
The drug safety review process.
Am J Ther. 2007 Mar-Apr;14(2):119. doi: 10.1097/MJT.0b013e31804d45f6.
引用本文的文献
1
A new Poisson and Bayesian-based method to assign risk and causality in patients with suspected hepatic adverse drug reactions: a report of two new cases of ticlopidine-induced hepatotoxicity.一种基于泊松分布和贝叶斯方法的疑似肝脏药物不良反应患者风险及因果关系判定新方法：两例噻氯匹定所致肝毒性新病例报告
Drug Saf. 2002;25(10):735-50. doi: 10.2165/00002018-200225100-00006.
Zotero 插件